Oncology

Sandoz has introduced its ready-to-use levoleucovorin injection to the US market.

Highest uninsured rates found in patients with testicular, stomach, and cervical cancers.

BRAF mutations commonly found in melanoma also seen in subset of lung cancer patients.

Introduction of protein to pancreatic cancer cells causes them to revert back to normal.

FDA finds that infusion pump did follow quality system regulations for medical devices that ensure safe use.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses the changing role of specialty pharmacy in cancer treatment.

Taking over-the-counter supplements beyond the recommended amount could increase cancer risk.

Suppression of Wnt signaling pathway shows promise.

Re-engineering antibodies allows them to selectively kill tumors.

Regulating PD-L1 protein that helps cancer evade immune system suggests new therapeutic approach.

The FDA has awarded Breakthrough Therapy status to crizotinib (Xalkori) for ROS1-positive non-small cell lung cancer.

Researchers determine mechanism for poor survival rates in African American patients with estrogen-receptor positive breast cancer.

Mild exercise found to improve fatigue and depression.

Mild cognitive impairment can set in prior to the start of therapy.

Selumetinib treats a rare disease where cancer cells form within eye tissues.

Record number of orphan drugs approved in 2014.

Itraconazole shows some promise in treatment of metastatic prostate cancer.

Study showed a median overall survival of nearly 3 years with Zytiga plus prednisone.

Donna M. Smith, PharmD, director of clinical affairs at Avella Specialty Pharmacy discusses how specialty pharmacists can help manage difficult lung cancer therapy.

Mortality gap in cancer deaths among African Americans and Caucasians may eventually disappear.

Study suggests substances in synthetic marijuana may damage human cell DNA.

Spat occurs with customer picking up cancer medication.

Abiraterone acetate (Zytiga) significantly prolongs survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.

Treatment will be available for clinical trials in patients with certain types of leukemia and non-Hodgkin lymphomas later this year.

Combination of nintedanib with docetaxel primarily depends on whether patients already had brain metastases.

Supplements containing creatine or androstenedione significantly increase disease risk.

Liquid bendamustine hydrochloride rapid infusion treats patients with chronic lymphocytic leukemia.

Low temperature plasmas found to induce high levels of DNA damage.